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ABSTRACT
Nab-paclitaxel (NPT) combination with gemcitabine (Gem) represents the standard 
chemotherapy for pancreatic ductal adenocarcinoma (PDAC). Genetic alterations of the 
RAS/RAF/MEK/ERK (MAPK) signaling pathway yielding constitutive activation of the 
ERK cascade have been implicated as drivers of PDAC. Inhibition of downstream targets 
in the RAS-MAPK cascade such as MEK remains a promising therapeutic strategy. The 
efficacy of trametinib (Tra), a small molecule inhibitor of MEK1/2 kinase activity, in 
combination with nab-paclitaxel-based chemotherapy was evaluated in preclinical 
models of PDAC. The addition of trametinib to chemotherapy regimens showed a 
trend for an additive effect on tumor growth inhibition in subcutaneous AsPC-1 and 
Panc-1 PDAC xenografts. In a peritoneal dissemination model, median animal survival 
compared to controls (20 days) was increased after therapy with NPT (33 days, a 
65% increase), Tra (31 days, a 55% increase), NPT+Tra (37 days, a 85% increase), 
NPT+Gem (39 days, a 95% increase) and NPT+Gem+Tra (49 days, a 145% increase). 
Effects of therapy on intratumoral proliferation and apoptosis corresponded with tumor 
growth inhibition. Trametinib effects were specifically accompanied by a decrease 
in phospho-ERK and an increase in cleaved caspase-3 and cleaved PARP-1 proteins. 
These findings suggest that the effects of nab-paclitaxel-based chemotherapy can 
be enhanced through specific inhibition of MEK1/2 kinase activity, and supports the 
clinical application of trametinib in combination with standard nab-paclitaxel-based 
chemotherapy in PDAC patients.
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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is among 
the most lethal malignancies in the US [1]. PDAC is 
currently the third most frequent cause of cancer deaths in 
the US and is expected to be the second deadliest cancer 
by 2030 [1, 2]. The 5-year survival rate in PDAC patients 
remains about 6% and the poor prognosis is attributed 
to several factors including late-stage diagnosis, an 
aggressive progression of the disease and high resistance 
to conventional therapies. Surgery remains the best option 
for the long-term survival of PDAC patients, however, 
only about 20% of patients are suitable for this procedure 
[3]. Furthermore, post-operative recurrence remains very 
common, and even after complete resection, the 5-year 
survival is only around 25% [1]. Therefore, improving 
systemic treatment strategies is highly desirable for PDAC 
patients. Gemcitabine (Gem) remained a standard therapy 
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for PDAC for more than 16-years despite only a minimal 
clinical benefit [4]. FOLFIRINOX is a combination 
chemotherapy regimen that increased the median survival 
of unresectable PDAC patients to approximately 11 months. 
However, this regimen has a high toxicity potential, limiting 
its use to only patients with good performance status [5]. 
Nab-paclitaxel (NPT) is a next-generation taxane that has 
demonstrated significant antitumor efficacy in several solid 
tumors. Nab-paclitaxel is an approved treatment for breast 
cancer, NSCLC and PDAC [6]. Nab-paclitaxel combined 
with gemcitabine has recently become the standard 
treatment for unresectable PDAC after demonstrating a 
1.8 months improvement in patient survival compared to 
gemcitabine monotherapy [7]. Due to the limited clinical 
efficacy of current cytotoxic chemotherapy regimens for 
PDAC patients, novel therapeutic approaches are urgently 
needed to further improve patient survival.    
Activation of ERK signaling due to mutations in 
the RAS/RAF/MEK/ERK (MAPK) pathway has been 
implicated in several cancers [8]. In PDAC, activating 
KRAS mutations occur at a frequency of 90% [9], rendering 
this a potential therapeutic target of great interest. 
Developing drugs that directly target mutant KRAS 
protein remains challenging due to target specificity issues 
[10]. Therefore, alternative strategies focus on inhibition 
of downstream targets of the RAS-MAPK cascade. MEK 
is one such protein kinase located downstream of RAS/
RAF, making it an attractive target for cancer therapy [11]. 
Trametinib (Tra, Supplementary Figure 1), a selective 
and reversible small molecule inhibitor of MEK1/2 
kinase activity, has demonstrated antitumor efficacy in 
preclinical studies of several tumor types, with the largest 
effect in tumors harboring mutant BRAF or Ras [12]. 
Furthermore, trametinib is an FDA-approved treatment 
for V600E-mutant metastatic melanoma patients as a 
single agent or in combination with dabrafenib [13, 14]. 
In a preclinical study with patient-derived xenografts of 
PDAC, trametinib showed significant antitumor effects 
[15]. In addition, the first clinical study of trametinib 
monotherapy in PDAC demonstrated potential activity 
[16]. In a recent phase II clinical trial in PDAC patients, 
trametinib combination with gemcitabine demonstrated 
a 1.7 months increase in median overall survival (OS) 
compared with the gemcitabine alone. However, this 
difference in OS was evaluated as non-significant as the 
observed separation was not durable with a hazard ratio 
of 0.98 [17]. Furthermore, in a phase II clinical study in 
KRAS mutant NSCLC patients, selumetinib, another MEK 
inhibitor, plus docetaxel showed significant improvements 
in response rate and progression-free survival (PFS) [18], 
indicating differences in the synergy of MEK inhibitors 
with gemcitabine compared with taxanes. In this study, we 
report the antitumor efficacy of trametinib in combination 
with nab-paclitaxel-based chemotherapy regimens in 
preclinical models of pancreatic cancer. 
RESULTS
Nab-paclitaxel-based chemotherapy regimens 
and trametinib reduce tumor growth
In an AsPC-1 subcutaneous xenograft model, nab-
paclitaxel alone, nab-paclitaxel plus gemcitabine and 
trametinib alone caused an inhibition in tumor growth while 
trametinib combination with chemotherapy regimens had a 
trend for additive effects (Figure 1A). Net tumor growth in 
different groups after 2-weeks of therapy was 432.6 mm3 in 
controls, 105.3 mm3 after NPT, 184 mm3 after Tra, 81 mm3 
after NPT+Tra, 37.3 mm3 after NPT+Gem and –8.1 mm3 
(tumor regression) after NPT+Gem+Tra (Figure 1B). 
Tumor weight at the completion of the experiment in 
different groups was 0.38 g in controls, 0.23 g in NPT, 
0.31 g in Tra, 0.23 g in NPT+Tra, 0.15 g in NPT+Gem and 
0.11 g in NPT+Gem+Tra (Figure 1C). In another Panc-1 
subcutaneous xenograft model, nab-paclitaxel, nab-paclitaxel 
plus gemcitabine and trametinib therapy also caused an 
inhibition in tumor growth rates with a trend for additive 
effects in combination groups (Figure 2A). Net tumor 
growth in different groups was 274.1 mm3 in controls, 
80.8 mm3 after NPT, 150.6 mm3 after Tra, 75.1 mm3 after 
NPT+Tra, 48.4 mm3 after NPT+Gem and 3.8 mm3 after 
NPT+Gem+Tra (Figure 2B). Tumor weight at the completion 
of the experiment in different groups was: 0.37 g in controls, 
0.15 g in NPT, 0.18 g in Tra, 0.13 g in NPT+Tra, 0.09 g in 
NPT+Gem and 0.077 g in NPT+Gem+Tra (Figure 2C). 
Also, in these two subcutaneous xenograft experiments, no 
disenable therapy-related toxicity was observed during the 
therapy period and there was no significant change in the 
body weight of mice in all groups (Figures 1D, 2D). 
Nab-paclitaxel-based chemotherapy regimens 
and trametinib increase animal survival 
In an AsPC-1 pancreatic cancer peritoneal 
dissemination model, animal survival in different groups, 
compared with controls (20 days) was increased after therapy 
with NPT (33 days, a 65% increase), Tra (31 days, a 55% 
increase), NPT+Tra (37 days, a 85% increase), NPT+Gem 
(39 days, a 95% increase) and NPT+Gem+Tra (49 days, a 
145% increase) (Figure 3A, 3B). No significant change in 
the body weight of mice was observed during 2-week therapy 
period, indicating that there was no discernable therapy-
associated toxicity in all therapy groups.
Nab-paclitaxel-based chemotherapy and trametinib: 
tumor cell proliferation and apoptosis
The antitumor mechanisms of nab-paclitaxel-based 
chemotherapy regimens and trametinib were investigated 
by IHC analysis of subcutaneous tumor tissues. 
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Ki67 staining demonstrated that nab-paclitaxel, 
nab-paclitaxel plus gemcitabine and trametinib decreased 
tumor cell proliferation and combination therapy groups 
demonstrated a trend for an additive effect. Intratumoral 
proliferative index, the percentage of Ki67-positive 
cells over the total number of cells per high-power field, 
in different therapy groups was: controls (45.4), NPT 
(21.8), Tra (26.6), NPT+Tra (15.1), NPT+Gem (13.3) and 
NPT+Gem+Tra (8.2) (Figure 4A).
TUNEL assay detected that nab-paclitaxel and 
trametinib monotherapies increased tumor cell apoptosis 
and the combination therapy groups demonstrated a trend 
for an additive effect. The apoptotic index readings, by 
therapy group, were: controls (0.013), NPT (0.055), 
Tra (0.043), NPT+Tra (0.072), NPT+Gem (0.064) and 
NPT+Gem+Tra (0.108) (Figure 4B). 
Further investigation of the tumor growth inhibitory 
action of nab-paclitaxel-based chemotherapy regimens and 
trametinib exhibited that trametinib significantly decreased 
ERK phosphorylation and concomitantly increased the 
expression of apoptosis-associated proteins cleaved 
caspase-3 and cleaved PARP-1 (Figure 5). 
Nab-paclitaxel-based chemotherapy and 
trametinib: In vitro cell viability and cellular 
targets
In vitro cell viability examination of human PDAC 
epithelial cells with different mutations [19], indicated 
that both, nab-paclitaxel plus gemcitabine and trametinib, 
suppressed cell proliferation. In the combination therapy 
groups, at high dose (10 µM), a statistically significant 
additive response on cell proliferation inhibition was 
observed in N+G+Tra compared with N+G or Tra groups 
for all the four cell lines tested (Figure 6). Nab-paclitaxel 
plus gemcitabine treatment dose-dependently inhibited 
cell proliferation, and at 10 µM concentration of each 
drug inhibition in proliferation was 47.6% (AsPC-1), 
66.6% (Panc-1), 51.7% (Mia PaCa-2) and 80% (CFPAC) 
(Figure 6). Addition of trametinib (10 µM) to the nab-
Figure 1: Antitumor activity of nab-paclitaxel-based chemotherapy regimens and trametinib in AsPC-1 tumor 
xenografts. AsPC-1 cells were subcutaneously injected into nude mice and treated with nab-paclitaxel-based chemotherapy regimens 
and trametinib for 2 weeks. (A) Tumor size as measured twice-weekly using calipers. (B) Net tumor growth, calculated by subtracting 
tumor volume on the first treatment day from that on the final day. (C) Mean tumor weight was calculated from final day tumor weights in 
each group, presented as a Box plot. (D) Mouse body weight was measured twice a week and presented as bar chart for the 2-week therapy 
period. Data are representative of mean values ± standard deviation from 5 mice per group.
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paclitaxel plus gemcitabine treatment group caused an 
additive effect and inhibition in cell proliferation in this 
combination group was 75% (AsPC-1), 82.6% (Panc-1), 
65.6% (Mia PaCa-2) and 89.4% (CFPAC) (Figure 6). 
Immunoblot analysis determined that trametinib blocked 
the expression of phospho-ERK and concomitantly 
increased the expression of cleaved caspase-3 and cleaved 
PARP-1 proteins (Figure 7). 
DISCUSSION
Pancreatic cancer is frequently refractory to cytotoxic 
and targeted therapies, mainly due to the marked genetic 
heterogeneity and resultant complexity in molecular 
signaling [20]. Specifically, PDACs exhibit a high 
frequency of activating mutations in the KRAS oncogene, 
inactivating mutations in tumor suppressor genes p16/
CDKN2A and TP53 and inactivation of the SMAD4 gene 
[21–23]. Activating mutation in the KRAS oncogene is a 
hallmark of PDAC as it is crucial for PDAC growth and 
progression and occurs in approximately 95% of patients 
[24]. Further, the importance of the KRAS oncogene in 
PDAC development has been demonstrated in genetically 
engineered mouse models [25, 26]. Therefore, investigating 
strategies for effective inhibition of KRAS signaling is 
critically important in pancreatic cancer research [25, 27]. 
Small molecule inhibitors of downstream targets of the 
RAS-RAF-MEK-ERK pathway are in clinical development 
and have shown promising efficacy in RAS/RAF-driven 
tumors [28, 29]. 
Trametinib has been shown to prevent RAS-
dependent MEK phosphorylation and cause prolonged 
inhibition of ERK signaling [12]. Trametinib is highly 
selective for their targets, which may lead to fewer off-target 
effects [30]. In PDAC, trametinib augmented combined 
treatment with EGFR and HER2 inhibitors in patient-
derived xenograft models [15, 31]. Early clinical studies in 
PDAC with trametinib monotherapy or its combination with 
Figure 2: Antitumor activity of nab-paclitaxel-based chemotherapy regimens and trametinib in Panc-1 tumor 
xenografts. Panc-1 cells were subcutaneously injected in nude mice and treated with nab-paclitaxel-based chemotherapy regimens and 
trametinib for 2 weeks. (A) Tumor size as measured twice-weekly using calipers. (B) Net tumor growth, calculated by subtracting tumor 
volume on the first treatment day from that on the final day. (C) Mean tumor weight was calculated from final day tumor weights in each 
group and is presented as a Box plot. (D) Mouse body weight was measured twice a week and presented as bar chart for the 2-week therapy 
period. Data are representative of mean values ± standard deviation from 5 mice per group.
Oncotarget5278www.impactjournals.com/oncotarget
gemcitabine showed promising results [16, 32]. Although a 
phase II clinical trial in untreated metastatic PDAC patients 
could not demonstrate significant clinical efficacy of the 
combination of gemcitabine and trametinib [17], another 
study in NSCLC with selumetinib as a MEK inhibitor 
demonstrated significant clinical benefits in combination 
with docetaxel, indicating the possibility of some synergy 
potential of MEK inhibitors with taxanes compared with 
gemcitabine [18]. Therefore, we explored the antitumor 
benefits of combining trametinib with the current standard 
of care chemotherapy regimen containing both the next-
generation taxane nab-paclitaxel and gemcitabine in 
preclinical models of pancreatic cancer. 
We detected a significant expression of phospho-
MEK and phospho-ERK (Supplementary Figure 2) in all 
seven PDAC cells tested, confirming the prevalence of 
the MAPK signaling cascade in PDAC cellular activation 
and progression. In subcutaneous xenografts of two 
aggressive KRAS-mutant cell lines, AsPC-1 and Panc-1, 
we determined that trametinib not only inhibited tumor 
growth as a monotherapy, but it also demonstrated a trend 
for an additive effect in combination with chemotherapy 
regimens, although it did not reach statistical significance 
(Figures 1, 2). The trend for additive effect was more 
pronounced in the NPT+Gem group compared to the 
NPT group. Tumor cell proliferation and apoptosis rate 
evaluated in tumor tissue correlated with the tumor growth 
experiment results, supporting a trend for an additive 
effect on decreased proliferation and increased apoptosis 
by addition of trametinib (Figure 4). Furthermore, the 
addition of trametinib to chemotherapy regimens caused 
an obvious and statistically significant increase in 
Figure 3: Prolongation of animal survival by nab-paclitaxel-based chemotherapy regimens and trametinib. 
(A) Schematic representation of experimental procedure. AsPC-1 cells (0.75 × 106) were injected intraperitoneally in NOD/SCID mice 
and treatment was started after 2 weeks with nab-paclitaxel, gemcitabine and trametinib for 2 weeks. (B) The curve represents the animal 
survival time from the beginning of therapy. Statistical group differences in survival time were calculated using logrank testing.
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animal survival in our peritoneal dissemination model 
(Figure 3). Smaller additive effects of trametinib in the 
subcutaneous model suggest the possibility of the local 
tumor microenvironment factors making MEK inhibition 
less relevant to PDAC growth compared with the more 
clinically relevant peritoneal dissemination model where 
MEK inhibition caused a significant improvement in the 
chemotherapy response. Target protein determination in 
protein lysates from subcutaneous xenografts showed 
that trametinib significantly decreased phosphorylated 
ERK and increased the expression of apoptosis-associated 
proteins, suggesting that the trametinib therapy is 
sufficiently affecting its target within the local tumor 
setting. Early MEK inhibitors such as PD0325901, 
selumetinib and cobimetinib blocked ERK activation, but 
concomitant interference with ERK-dependent negative 
feedback resulted in the accumulation of phospho-MEK 
and rebound in ERK signaling [33, 34]. Newer MEK 
inhibitors including trametinib cause minimal to no 
increase in phospho-MEK or recovery in ERK activity, 
resulting in lasting inhibition of MAPK pathway and 
superior antitumor activity [34]. 
Previous studies in our laboratory have employed 
an established peritoneal dissemination model of PDAC 
to study animal survival using KRAS-mutant AsPC-1 cells 
that resembles the human disease in its aggressiveness and 
metastatic progression [35, 36]. With this approach, we 
observed that animal survival was improved by trametinib 
with and without nab-paclitaxel or nab-paclitaxel plus 
gemcitabine. More importantly, trametinib augmented 
nab-paclitaxel-based chemotherapy effects for the 
greatest improvement in animal survival. These results 
are consistent with a recent study demonstrating that 
trametinib in combination with gemcitabine had enhanced 
antitumor efficacy in a patient-derived xenograft model 
of PDAC in inhibiting growth rate of liver metastases 
and increasing PFS [37]. This observation is through 
our data extended to nab-paclitaxel, which appears to 
be specifically suited for in vivo therapy benefits when 
combined with trametinib. Although the appropriate 
Figure 4: Mechanisms of antitumor activity of nab-paclitaxel-based chemotherapy regimens and trametinib. Nude mice 
were subcutaneously injected with AsPC-1 cells and treated with nab-paclitaxel, gemcitabine and trametinib for 2 weeks. (A) Intratumoral 
proliferation was measured by immunostaining tissue sections for Ki67 nuclear antigen. Ki67-positive cells were counted in five different 
high power fields. (B) Intratumoral apoptosis was measured by staining tumor tissue section with TUNEL procedure. TUNEL-positive 
apoptotic cells were counted in five different high power fields. For both immunostaining experiments, slides were photographed under a 
fluorescent microscope and the data are expressed as the mean ± standard deviation. 
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sequence for the administration of MEK inhibitor and 
chemotherapy agents has been shown to impact clinical 
outcomes [17, 38], we have not evaluated the effects of 
varied dosing schedule of these drugs. In this study, nab-
paclitaxel effects on enhanced tissue distribution and 
tumor penetration of drugs might be partially responsible 
for enhanced antitumor response in combination therapy 
groups as nab-paclitaxel therapy was started together with 
trametinib and a day before gemcitabine [39]. 
In vitro cell viability analysis revealed that trametinib 
inhibited proliferation of KRAS-mutant PDAC cells while 
the combination of trametinib with nab-paclitaxel plus 
gemcitabine had additive effects on inhibition in cell 
proliferation at high dose level (10 µM). Among these 
cells, AsPC-1 cells were most sensitive to trametinib and 
a significant decrease in cell viability was observed at 
all dose levels, and a very little additive benefit on cell 
viability inhibition was observed by addition of trametinib 
to chemotherapy. Other PDAC cells tested showed a small 
effect on cell viability at low dose levels and the effect was 
significant at high dose levels. The differential sensitivity of 
pancreatic cancer cells to MEK inhibition can be attributed 
to the KRAS mutational subtype, copy number and the 
presence of PIK3CA co-mutation [40, 41]. In a phase 1 
study, the maximum plasma concentration of trametinib 
was 62.8 ng/ml (~0.1 µM) [16]. Similar to the target protein 
evaluation in tumor lysates, protein lysates from AsPC-1 
and Panc-1 cells demonstrated a dramatic decrease in 
ERK phosphorylation and an increase in apoptosis-related 
proteins by trametinib treatment. These findings further 
indicate that the antitumor response of trametinib is linked 
to blocking ERK induced molecular signaling changes that 
are accountable for tumor cell proliferation and survival. 
PDAC progression is multifactorial involving 
increased tumor cell proliferation, differentiation, migration, 
angiogenesis, epithelial-to-mesenchymal transition, 
desmoplasia and immune system evasion, and most of 
these mechanisms have been shown to be affected by or 
regulated through the RAS-RAF-MEK-ERK signaling 
pathway [42, 43]. We have previously demonstrated that 
nab-paclitaxel-based chemotherapy has antitumor responses 
based on its antiproliferative, antistromal and proapoptotic 
effects [44]. Therefore, the possible molecular mechanisms 
for the improvement in antitumor responses of nab-
Figure 5: Nab-paclitaxel-based chemotherapy regimens and trametinib effects on their molecular targets in vivo. 
Tumor lysates were prepared from tumor tissues obtained from AsPC-1 tumor-bearing mice and were analyzed by immunoblotting. Data 
are representative of pooled lysates obtained from tumor sections of at least 5 mice in each therapy group. The intensity of bands was 
quantitated by densitometry and is represented in the bar graph after normalizing values with corresponding total protein expression or 
GAPDH expression. 
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paclitaxel-based chemotherapy regimen by trametinib may 
likely be caused by not only augmenting antiproliferative 
and proapoptotic activities but also by inhibiting other 
tumorigenic pathways including angiogenesis [45]. 
Based on the fact that the RAS-RAF-MEK-ERK 
pathway is one of the most frequently dysregulated 
pathways in PDAC, MEK inhibitors have shown promising 
antitumor activity, either alone or in combination with 
other anticancer drugs [46–48]. Trametinib is a new 
generation MEK1/2 inhibitor, which is highly selective 
for these targets. Compared with other MEK inhibitors, 
trametinib has several advantages including a favorable 
pharmacokinetic profile, long half-life and manageable 
toxicity [16, 49]. In the present study, no discernible 
treatment-associated toxicity was observed during a 
2-week therapy period, however, toxicity associated with 
long-term therapy of trametinib in combination with 
nab-paclitaxel-based chemotherapy regimens remains 
to be elucidated. In conclusion, our study indicates that 
trametinib, a MEK1/2 inhibitor blocking KRAS activating 
mutation induced RAF-MEK-ERK tumorigenic signaling, 
is an effective mechanism-specific antitumor agent, and 
it can improve nab-paclitaxel-based chemotherapy effects 
in PDAC. These results strongly support the rationale of 
blocking downstream targets of KRAS-mutation driven 
signaling and indicate the potential of trametinib as a 
targeting agent in combination with nab-paclitaxel-based 
chemotherapy regimens for clinical PDAC therapy. 
MATERIALS AND METHODS
Cell culture and reagents
Human PDAC cell lines (AsPC-1, BxPC-3, 
CFPAC, Mia PaCa-2 and Panc-1) were purchased from 
the American Type Culture Collection (ATCC, Rockville, 
MD). Cell lines were tested and authenticated by ATCC. 
The most common mutations in all the cell lines used in 
Figure 6: Nab-paclitaxel plus gemcitabine and trametinib inhibit in vitro PDAC cell proliferation. PDAC cells (AsPC-1, 
Panc-1, Mia PaCa-2, CFPAC) were plated on 96-well plates and treated with 100 nM to 10 μM concentrations of nab-paclitaxel, gemcitabine 
and trametinib. After 72 hours, 10 μl WST-1 reagent was added in each well and incubated for 2 additional hours. The absorbance at 450 nm 
was measured using a microplate reader. The resulting number of viable cells was calculated by measuring absorbance of color produced 
in each well. Data are the mean ± SD of triplicate determinations. The p values represent significance of the difference between the control 
and treated groups.
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this study are as follows: AsPC-1 (KRAS, p53, p16), Panc-1 
(KRAS, p53, p16), Mia PaCa-2 (KRAS, p53, p16) and 
CFPAC (KRAS, p53, SMAD4) [19]. Cells were initially 
grown and multiple aliquots were cryopreserved. All the 
cell lines were used within 6 months after reexpansion 
in culture. Cells were cultured in DMEM or RPMI 1640 
medium (Sigma Chemical Co. St. Louis, MO) containing 
10% FBS and maintained at 37°C in a humidified incubator 
with 5% CO2 and 95% air. Nab-paclitaxel was obtained 
from Celgene Corporation (Summit, NJ). Gemcitabine and 
trametinib were purchased from LC labs (Woburn, MA). 
The cell proliferation reagent WST-1 was purchased from 
Roche Diagnostic Corporation (Indianapolis, IN). 
Cell viability assay
Cell viability was evaluated by the colorimetric 
WST-1 assay as previously described [50]. Briefly, PDAC 
cells (4,000 to 5,000 cells per well) were plated in a 96-
well plate in regular cell growth medium containing 10% 
FBS. After 16 hours the medium was replaced with low 
serum medium containing 2% FBS and the cells were 
treated with 100 nM to 10 µM concentrations of nab-
paclitaxel, gemcitabine and trametinib. After 72 hours, 
10 µl WST-1 reagent was added in each well followed 
by additional incubation for 2 hours. The absorbance was 
measured at 450 nm using a microplate reader. 
Western blot analysis
Protein lysates were prepared by treating sub-
confluent cells with nab-paclitaxel (10 µM), gemcitabine 
(10 µM) and trametinib (10 µM), and lysed after 16 hours 
for Western blotting as previously described [50]. Protein 
lysates of subcutaneous tumors were prepared by snap 
freezing tumor tissues in liquid nitrogen and stored at 
–80°C. These tumor tissues were suspended in lysis buffer 
and homogenized using the Bullet Blender Homogenizer 
(Next Generation, Averill Park, NY), and extracts were 
sonicated on ice. Proteins in supernatants were separated 
by SDS-PAGE and transferred to PVDF membranes (Bio-
Rad, Hercules, CA). The membranes were incubated 
overnight at 4°C with the following antibodies: total 
ERK1/2, phospho-ERK1/2 (Thr202/Tyr204), cleaved 
caspase-3, cleaved PARP-1 and GAPDH (Cell Signaling 
Technology, Beverly, MA). The membranes were then 
incubated with the corresponding HRP-conjugated 
secondary antibodies (Pierce Biotechnologies, Santa Cruz, 
CA) for 1 to 2 hour. Protein bands were visualized using 
the enhanced chemiluminescence reagent (SignalFire, Cell 
Figure 7: Nab-paclitaxel-based chemotherapy regimens and trametinib effects on their molecular targets in vitro. 
A sub-confluent monolayer of human PDAC cells AsPC-1 and Panc-1 was treated with nab-paclitaxel (10 μM), gemcitabine (10 μM) and 
trametinib (10 μM), either alone or in combination for 16 hours. Total cell extracts were analyzed by immunoblotting. The intensity of 
bands was quantitated by densitometry and is represented in the bar graph after normalizing values against corresponding total protein 
expression or GAPDH expression. Data are representative of two independent experiments with similar results. 
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Signaling) with an Image360 system and quantitated by 
densitometry.
Animal experiments
All animals were housed in a pathogen-free 
facility with access to food and water ad libitum. Animal 
experiments were performed in accordance with the 
Institutional Animal Care and Use Committee (IACUC) 
at the Indiana University School of Medicine (South 
Bend, IN). Female nonobese diabetic/severe combined 
immunodeficient (NOD/SCID) mice (4 to 6 weeks old) 
were subcutaneously injected with AsPC-1 cells (7.5 × 105) 
or Panc-1 cells (10 × 106) as previously described [44]. 
Two weeks after tumor cell injection, all mice had a 
measurable tumor. Mice were then randomized (n = 4 
to 6 per group) to receive PBS (control), nab-paclitaxel 
(5 mg/kg, twice a week), gemcitabine (50 mg/kg, 
twice a week) and trametinib (1 mg/kg, 5 times a week) 
via intraperitoneal injection for next 2 weeks. The tumor 
size was measured twice weekly, and tumor volume (V) 
was calculated using the formula V = ½ (Length × Width2). 
Net tumor growth was calculated by subtracting tumor 
volume on the first therapy day from that on the last day. 
Mice were euthanized after completion of treatment, 
tumors were dissected and processed for histological, 
immunohistochemical and Western blot analysis.
Animal survival studies were performed using 
female NOD/SCID mice (4–6 weeks of age) as 
previously described [51]. Briefly, the mice were injected 
intraperitoneally with AsPC-1 (7.5 × 105) cells and two 
weeks after tumor cell injection, mice were randomized 
(n = 6 to 8 per group) to receive PBS (control), nab-
paclitaxel (5 mg/kg, twice a week), gemcitabine 
(50 mg/kg, twice a week) and trametinib (1 mg/kg, 
5 times a week) via IP injection for two weeks. Animals 
were euthanized when moribund according to predefined 
criteria [52, 53]. Animal survival was evaluated from the 
first day of treatment until death.
Immunohistochemistry and immunofluorescence
Standard immunohistochemistry protocol was 
followed to stain the tumor tissue sections, as previously 
described [54]. Briefly, tumor tissue samples were fixed 
in 4% paraformaldehyde, embedded in paraffin, tissue 
sections were cut (5 µm), deparaffinized and rehydrated. 
The tissue sections were incubated with 1:200 dilution 
of Ki67 antibody (ab15580, Abcam, Cambridge, MA) 
followed by incubation with 1:200 dilution of anti-rabbit-
Cy3 secondary antibody (Jackson ImmunoResearch 
Laboratories, West Grove, PA). Slides were mounted 
using a mounting solution containing 4ʹ,6-diamidino-
2-phenylindole (DAPI) (Invitrogen, Carlsbad, CA). 
The intratumoral proliferative index was determined by 
calculating the Ki67-positive cells from five different 
high-power fields (HPF) in a blinded manner in each 
group. Intratumoral apoptotic activity was evaluated 
by staining tissue sections with “Apoptag Apoptosis 
Detection Kit” according to the manufacturer’s (Millipore, 
Temecula, CA) instructions. The apoptotic index was 
calculated by dividing the number of TUNEL-positive 
cells by the total number of cells per HPF in a blinded 
manner in each group. Fluorescence microscopy was used 
to detect fluorescent signals using the IX81 Olympus 
microscope equipped with a Hamamatsu Orca digital 
camera (Hamamatsu Corporation, Bridgewater, NJ) and a 
disk-scanning unit (DSU) spinning disk confocal system 
using Slidebook software (Intelligent Imaging Innovations, 
Philadelphia, PA).
Statistical analysis
Statistical analysis for in vivo tumor growth studies 
was performed by one-way ANOVA for multiple group 
comparisons and Student’s t-test for the individual group 
comparisons. Survival study statistics were performed 
using logrank group comparison (GraphPad Prism 6.0). 
P values less than 0.05 were considered statistically 
significant. In vitro cell proliferation data are expressed as 
the mean ± standard deviation. Statistical significance was 
analyzed by the two-tailed Student’s t-test using GraphPad 
Prism 6.0 Software (GraphPad Software, San Diego, CA) 
for individual group comparisons. 
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